Ramsay Générale de Santé (GDS) H2 2023 earnings summary

Executive summary

• Revenue rose 6.5% year-over-year to €5.0 billion, driven by activity growth across all regions.

• EBITDA declined 1.7% to €610.9 million, with margin down to 12.2% from 13.2% due to lower subsidies and inflationary pressures.

• Net result swung to a loss of €53.9 million from a profit of €49.4 million last year, impacted by higher debt costs and lower operating margins.

• Strategic investments continued in imaging, primary care, and mental health, including the acquisition of 12 Cosem centers in France.

• Successful refinancing extended €1.65 billion in senior debt maturities to 2029-2031, supporting long-term strategy.

Financial highlights

• Organic revenue growth reached 7.5% at constant scope and exchange rates.

• France revenue up 7.1%, Nordic countries up 8.8% at constant scope and FX, but only 5.3% reported due to currency headwinds.

• EBITDA margin fell by 1.0 point to 12.2%, mainly due to a €107 million drop in government subsidies.

• Operating income down 33.2% to €160.6 million; recurring operating income down 15.6% to €184.2 million.

• Net financial debt at €3,610.9 million, with net leverage (pre-IFRS16) at 4.9x.

Outlook and guidance

• Strategic plan "Yes We Care 2025" continues, focusing on integrated care, digitalization, and sustainability.

• Recent refinancing provides a stable long-term funding framework for growth and transformation.

• Ongoing cost optimization and productivity measures to counteract inflation and funding gaps.